Search results for "immunoglobulin G"

showing 10 items of 308 documents

Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept…

2012

Objective: To evaluate the risk of serious infections (SIs) in RA patients receiving anti-TNF therapy on the basis of the data included in the GISEA register. METHODS: The study involved 2769 adult patients with long-standing RA (mean age 53.2±13.4years; mean disease duration 9.0±8.3years) enrolled in the GISEA register, who had been treated for at least 6months with TNF inhibitors or had discontinued therapy due to SI: 837 (30%) treated with infliximab (IFN), 802 (29%) with adalimumab (ADA), and 1130 (41%) with etanercept (ETN). RESULTS: 176 patients had experienced at least one of the 226 Sis during the 9years of treatment with an anti-TNF agent, an overall incidence of 31.8/1000 patient-…

Malerheumatoid arthritisArthritisReceptors Tumor Necrosis FactorEtanerceptEtanerceptArthritis RheumatoidAdalimumab; Adult; Aged; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antirheumatic Agents; Arthritis Rheumatoid; Etanercept; Female; Humans; Immunoglobulin G; Incidence; Infection; Infliximab; Male; Middle Aged; Receptors Tumor Necrosis Factor; Registries; Tumor Necrosis FactorsRheumatoidadalimumabMonoclonalReceptorsImmunology and AllergyRegistriesinfectionsHumanizedAnti-TNF agents; GISEA register; Infections; Predictive factorsIncidence (epidemiology)IncidenceAntibodies MonoclonalAnti-TNF agentsMiddle AgedRheumatoid arthritisAntirheumatic AgentsCohortTumor Necrosis FactorsFemaleInfectionPredictive factorsmedicine.druganti-TNF; serious infections; rheumatoid arthritisAdultmedicine.medical_specialtyanti-TNF therapy; infections; rheumatoid arthritis; adalimumab; etanercept; infliximabanti-TNF therapyserious infectionsImmunologyInfections rheumatoid arthritis anti-TNF therapyAntibodies Monoclonal HumanizedInfectionsAntibodiesInternal medicinemedicineAdalimumabHumansAgedGISEA registerbusiness.industryArthritisAdalimumabanti-TNFGISEA register; Infections; Anti-TNF agents; Predictive factors; Adalimumab; Adult; Aged; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antirheumatic Agents; Arthritis Rheumatoid; Etanercept; Female; Humans; Immunoglobulin G; Incidence; Infection; Infliximab; Male; Middle Aged; Receptors Tumor Necrosis Factor; Registries; Tumor Necrosis Factorsmedicine.diseaseInfliximabInfliximabConcomitantImmunoglobulin GImmunologyTumor Necrosis Factor InhibitorsbusinessTumor Necrosis Factorinfliximabetanercept
researchProduct

Immunoglobulin M seropositivity for Toscana virus in a random population sample in Sicily.

2012

Summary Objectives High Toscana virus (TOSV) antibody seropositivity rates have been documented in the last decade, especially in the Mediterranean area. It is unclear if these rates are associated with a recent or past exposure to the virus. This is of importance, as primary infection can cause neurologic complications, especially in adults. The aim of the present study was to assess the current active TOSV circulation in western Sicily. Methods A cross-sectional seroprevalence study was conducted on 271 individuals aged 4–92 years, sampled from the general population of a small city. Each participant completed a self-administered questionnaire and provided serum, which was analyzed for th…

Microbiology (medical)AdultMaleAdolescentCross-sectional studyPopulationSettore MED/42 - Igiene Generale E ApplicataAntibodies ViralBunyaviridae InfectionsArticleYoung AdultSeroepidemiologic StudiesMedicineSeroprevalenceHumansSeroconversioneducationChildSicilyAgedToscana virusAged 80 and overeducation.field_of_studybiologybusiness.industryToscana virusSandfly fever Naples virusGeneral MedicineMiddle Agedbiology.organism_classificationIgM seropositivityInfectious DiseasesCross-Sectional StudiesPhlebovirusImmunoglobulin MImmunoglobulin MChild PreschoolImmunoglobulin GImmunologySandfly fever Naples virusbiology.proteinFemalebusinessDemographyInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
researchProduct

PREVALENCE OF PERTUSSIS IgG ANTIBODIES IN CHILDREN IN PALERMO, ITALY

1989

The prevalence of IgG antibodies to Bordetella pertussis in a sample of 615 1-12-year-old unvaccinated children in Palermo was estimated by ELISA. The overall prevalence was 56%; it increased from 24% in one to three-year-old children to 67% in 11-12-year-old children (p less than 0.01). IgG antibody prevalence was not associated with the father's years of schooling (OR 1), nor with the family size (OR 1.3; C.I. 95% = 0.8-2.2). For children aged one the three years, serological results showed that the history of pertussis reported by parents in questionnaires gave high specificity (93.2%) and negative predictive value (85.4%). Our seroepidemiological study evidences a great exposure of chil…

Microbiology (medical)Bordetella pertussisPediatricsmedicine.medical_specialtyWhooping CoughEnzyme-Linked Immunosorbent AssaySensitivity and SpecificitySerologyPredictive Value of TestsSeroepidemiologic StudiesEpidemiologyPrevalencemedicineHumansChildAntibody prevalencebiologybusiness.industryInfantGeneral MedicineElisa assaybiology.organism_classificationPredictive valueInfectious DiseasesItalyEl NiñoChild PreschoolImmunoglobulin Gbiology.proteinAntibodybusiness
researchProduct

Diagnosis of systemic candidiasis by enzyme immunoassay detection of specific antibodies to mycelial phase cell wall and cytoplasmic candidal antigens

1993

Diagnosis of systemic Candida infections was attempted by the use of an enzyme-linked immunosorbent assay (EIA) to detect IgG antibodies towards cell wall-bound and cytoplasmic candidal antigens. Cell wall antigens were sequentially solubilized by treatment of germinated blastoconidia of Candida albicans (ATCC 26555 strain) with beta-mercaptoethanol (beta ME extract) and digestion with Zymolyase 20T, a beta-glucanase preparation (Zymolyase extract). Protoplasts obtained after treatment with Zymolyase were osmotically lysed (cytoplasmic antigens). Sera were obtained from patients with systemic (n = 28) and superficial (n = 46) candidiasis. Control sera were obtained from normal healthy indiv…

Microbiology (medical)CytoplasmAntigens FungalBlotting WesternEnzyme-Linked Immunosorbent AssaySensitivity and SpecificityBlastoconidiumMicrobiologyFungal ProteinsMannansAntigenCell WallCandida albicansmedicineHumansCandida albicansAntibodies FungalMannanMembrane Glycoproteinsbiologymedicine.diagnostic_testCandidiasisGeneral Medicinebiology.organism_classificationmedicine.diseaseCorpus albicansInfectious DiseasesImmunoglobulin GImmunoassaybiology.proteinSystemic candidiasisAntibodyLatex Fixation TestsEuropean Journal of Clinical Microbiology & Infectious Diseases
researchProduct

Prediction of pneumococcal conjugate vaccine effectiveness against invasive pneumococcal disease using opsonophagocytic activity and antibody concent…

2011

ABSTRACT We compared the abilities of two serological readouts, antipolysaccharide IgG antibody concentrations and opsonophagocytic activity (OPA) titers, to predict the clinical effectiveness of the 7-valent pneumococcal conjugate vaccine (7vCRM) against invasive pneumococcal disease (IPD). We also assessed the accuracy of the previously established thresholds for GlaxoSmithKline's enzyme-linked immunosorbent assay with 22F adsorption (22F-ELISA) (≥0.2 μg/ml) and OPA assay (titer, ≥8) in predicting effectiveness. We showed that following a 3-dose 7vCRM primary vaccination, the serological response rates as determined using thresholds of ≥0.2 μg/ml IgG and an OPA titer of ≥8 corresponded we…

Microbiology (medical)Heptavalent Pneumococcal Conjugate VaccineClinical BiochemistryImmunologyEnzyme-Linked Immunosorbent AssayBiologyPneumococcal conjugate vaccineImmunoglobulin GSerologyPneumococcal VaccinesImmune systemPhagocytosisHeptavalent Pneumococcal Conjugate VaccinemedicineImmunology and AllergyHumansmedicine.diagnostic_testOpsonin ProteinsVaccine ResearchVirologyAntibodies BacterialTiterImmunoassayImmunoglobulin GImmunologybiology.proteinAntibodymedicine.drugClinical and vaccine immunology : CVI
researchProduct

Development of novel immunoglobulin G (IgG), IgA, and IgM enzyme immunoassays based on recombinant Puumala and Dobrava hantavirus nucleocapsid protei…

2006

ABSTRACT Human infections with Asian and European hantaviruses can result in hemorrhagic fever with renal syndromes of differing severities characterized by renal dysfunction and sometimes by pulmonary symptoms. For the serological detection of human infections by hantaviruses relevant for Europe, we developed monoclonal antibody capture immunoglobulin G (IgG) and IgA enzyme-linked immunosorbent assays (ELISAs) based on yeast-expressed nucleocapsid proteins of Puumala and Dobrava hantaviruses. Moreover, for diagnosis of acute infections, μ-capture IgM ELISAs were established with nucleocapsid proteins expressed in Drosophila melanogaster Schneider S2 cells. The cutoff values of the ELISAs w…

Microbiology (medical)Immunoglobulin AOrthohantavirusvirusesHantavirus InfectionsClinical BiochemistryImmunologyEnzyme-Linked Immunosorbent AssaySaccharomyces cerevisiaeAntibodies ViralPuumala virusSensitivity and SpecificityVirusImmunoglobulin GSerologyImmunology and AllergyAnimalsHumansHantavirusbiologyNucleocapsid Proteinsbiology.organism_classificationVirologyRecombinant ProteinsImmunoglobulin ADrosophila melanogasterImmunoglobulin MImmunoglobulin MImmunoglobulin Gbiology.proteinPuumala virusMicrobial ImmunologyHantavirus InfectionClinical and vaccine immunology : CVI
researchProduct

Evaluation of the Architect Epstein-Barr Virus (EBV) Viral Capsid Antigen (VCA) IgG, VCA IgM, and EBV Nuclear Antigen 1 IgG Chemiluminescent Immunoas…

2014

ABSTRACTCommercial immunoassays for detecting IgG and IgM antibodies against Epstein-Barr virus (EBV), viral capsid antigens (VCA), and IgGs toward EBV nuclear antigen-1 (EBNA-1) are routinely used in combination to categorize EBV infection status. In this study, we evaluated the performances of the Architect EBV VCA IgG, VCA IgM, and EBNA-1 IgG chemiluminescent microparticle assays (CMIAs) in EBV serological analyses using indirect immunofluorescence assays and anticomplement immunofluorescence assays as the reference methods for VCA IgG, VCA IgM, and EBNA-1 IgG antibody detection, respectively. A total of 365 serum samples representing different EBV serological profiles were included in t…

Microbiology (medical)MaleEpstein-Barr Virus InfectionsHerpesvirus 4 HumanClinical BiochemistryImmunologyFluorescent Antibody Techniquemedicine.disease_causeImmunofluorescenceAntibodies ViralSensitivity and SpecificityImmunoglobulin GSerologyAntigenhemic and lymphatic diseasesDiagnostic Laboratory Immunologyotorhinolaryngologic diseasesImmunology and AllergyMedicineHumansChildAntigens ViralImmunoassaymedicine.diagnostic_testbiologybusiness.industryDiagnostic Tests RoutineInfantVirologyEpstein–Barr virusstomatognathic diseasesEpstein-Barr Virus Nuclear AntigensImmunoglobulin MImmunoglobulin MImmunoassayChild PreschoolImmunoglobulin GImmunologyLuminescent Measurementsbiology.proteinCapsid ProteinsFemaleAntibodybusiness
researchProduct

Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.

2006

Combination vaccines against common childhood diseases are widely used, provide an improved coverage, are more convenient and are more cost-effective than multiple injections. We conducted a study to evaluate the safety and immunogenicity of a combined measles-mumps-rubella-varicella (MMRV) candidate vaccine in comparison with the separate administration of licensed measles-mumps-rubella (MMR; Priorix) and varicella (V; Varilrix) vaccines.Healthy children 12-18 months of age received 2 doses of MMRV vaccine (3 lots) 6-8 weeks apart (MMRV group) or 1 dose of MMR vaccine administered concomitantly with 1 dose of varicella vaccine, followed by a second dose of MMR at 6-8 weeks later (MMR+V gro…

Microbiology (medical)MaleHerpesvirus 3 HumanFeverPainHyperemiamedicine.vaccineAntibodies ViralRubellaMeaslesCombination vaccinesChickenpox VaccinemedicineHumansVaccines CombinedMeasles mumps rubella varicellaMMRV vaccinebusiness.industryImmunogenicityvirus diseasesInfantmedicine.diseaseInfectious DiseasesMumps virusMeasles virusImmunoglobulin GPediatrics Perinatology and Child HealthImmunologyFemaleViral diseasebusinessMeasles-Mumps-Rubella VaccineThe Pediatric infectious disease journal
researchProduct

Anti-16-kilodalton mycobacterial protein immunoglobulin M levels in healthy but purified protein derivative-reactive children decrease after chemopro…

2007

ABSTRACT Serum responses against Mycobacterium tuberculosis HSP16 were determined for children with tuberculosis (TB) and for healthy purified protein derivative (PPD)-positive and PPD-negative children. Immunoglobulin G (IgG) and IgM responses were higher for TB patients than for other groups. After chemotherapy, IgM and IgG responses decreased for TB patients and PPD-positive subjects. Monitoring of anti- M. tuberculosis HSP16 responses could assist in the management of pediatric TB.

Microbiology (medical)TuberculosisAdolescentChaperoninsmedicine.medical_treatmentClinical BiochemistryImmunologyAntitubercular AgentsTuberculinEnzyme-Linked Immunosorbent AssayTuberculinChemopreventionImmunoglobulin GMicrobiologyKilodaltonMycobacterium tuberculosisBacterial ProteinsmedicineHumansTuberculosisImmunology and AllergyChildChemotherapyMycobacterium tuberculosis IgMpurified protein derivative chemoprophylaxisbiologybusiness.industryClinical and Diagnostic Laboratory ImmunologyMycobacterium tuberculosisbiology.organism_classificationmedicine.diseaseImmunoglobulin MImmunoglobulin MChild PreschoolImmunoglobulin GImmunologyChemoprophylaxisbiology.proteinbusiness
researchProduct

Determination of enrichment factors for modified RNA in MeRIP experiments

2019

In the growing field of RNA modification, precipitation techniques using antibodies play an important role. However, little is known about their specificities and protocols are missing to assess their effectiveness. Here we present a method to assess enrichment factors after MeRIP-type pulldown experiments, here exemplified with a commercial antibody against N6-methyladenosine (m6A). Testing different pulldown and elution conditions, we measure enrichment factors of 4-5 using m6A-containing mRNAs against an unmodified control of identical sequence. Both types of mRNA carry 32P labels at different nucleotides, allowing their relative quantification in a mixture after digestion to nucleotides…

Models MolecularAdenosineAbsolute quantificationMethylationProtein Structure SecondaryGeneral Biochemistry Genetics and Molecular BiologyViral Proteins03 medical and health sciencesAdenosine TriphosphateRNA modificationEscherichia coliHumansImmunoprecipitationProtein Interaction Domains and MotifsNucleotideRNA MessengerMolecular Biology030304 developmental biologychemistry.chemical_classification0303 health sciencesMessenger RNACell-Free SystemChemistryElution030302 biochemistry & molecular biologyRNADNA-Directed RNA PolymerasesBiochemistryImmunoglobulin GIsotope LabelingChromatography Thin LayerPhosphorus RadioisotopesProtein BindingMethods
researchProduct